Market closed
Inhibrx Biosciences/$INBX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Inhibrx Biosciences
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Ticker
$INBX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
169
Website
INBX Metrics
BasicAdvanced
$181M
0.10
$119.38
-
-
Price and volume
Market cap
$181M
52-week high
$18.95
52-week low
$10.80
Average daily volume
91K
Financial strength
Current ratio
4.705
Quick ratio
4.478
Total debt to equity
1.028
Management effectiveness
Valuation
Price to earnings (TTM)
0.105
Price to revenue (TTM)
115.31
Price to book
1.01
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-1.212
Growth
INBX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
INBX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Inhibrx Biosciences stock?
Inhibrx Biosciences (INBX) has a market cap of $181M as of February 26, 2025.
What is the P/E ratio for Inhibrx Biosciences stock?
The price to earnings (P/E) ratio for Inhibrx Biosciences (INBX) stock is 0.1 as of February 26, 2025.
Does Inhibrx Biosciences stock pay dividends?
No, Inhibrx Biosciences (INBX) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Inhibrx Biosciences dividend payment date?
Inhibrx Biosciences (INBX) stock does not pay dividends to its shareholders.
What is the beta indicator for Inhibrx Biosciences?
Inhibrx Biosciences (INBX) does not currently have a Beta indicator.